Ferritin to Erythrocyte Sedimentation Rate Ratio: Simple Measure to Identify Macrophage Activation Syndrome in

Esraa M A Eloseily1, Francesca Minoia2, Courtney B Crayne3

  • 1Assiut University, Assiut, Egypt, and Pediatric Rheumatology University of Alabama at Birmingham.

ACR Open Rheumatology
|November 29, 2019
PubMed
Abstract

Insights

The ferritin:ESR ratio aids in diagnosing macrophage activation syndrome (MAS) in systemic juvenile idiopathic arthritis (sJIA). Serum ferritin alone effectively screens for MAS in febrile children, improving early detection and management.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Clinical Diagnostics

Background:

  • Macrophage activation syndrome (MAS) is a severe complication of systemic juvenile idiopathic arthritis (sJIA).
  • Current classification criteria for MAS in sJIA are less effective with modern therapies.
  • Early diagnosis of MAS is crucial for patient outcomes.

Purpose of the Study:

  • To evaluate the ferritin:erythrocyte sedimentation rate (ESR) ratio for diagnosing MAS in sJIA.
  • To assess serum ferritin as a standalone screening tool for MAS across various etiologies.
  • To improve diagnostic accuracy for MAS in critically ill children.

Main Methods:

  • Analysis of international sJIA patient cohorts with and without MAS.
  • Assessment of hospitalized patients with systemic infection (SI) and MAS of multiple etiologies.
  • Construction of receiver operating characteristic (ROC) curves and calculation of area under the curve (AUC) for ferritin:ESR ratio and ferritin levels.

Main Results:

  • A ferritin:ESR ratio of 21.5 demonstrated 82% sensitivity and 78% specificity for sJIA-MAS.
  • Serum ferritin alone achieved 95% sensitivity and 89.3% specificity for identifying all-cause MAS in febrile hospitalized children.

Conclusions:

  • The ferritin:ESR ratio offers a practical diagnostic method for MAS in sJIA patients.
  • Serum ferritin serves as a valuable screening tool for detecting MAS in febrile hospitalized children.
  • These biomarkers can enhance the early identification and management of MAS.